Clinical trial
Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels…
NCT00170833 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00170833 |
|---|---|
| Title | Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients |
| Official title | A Prospective, Multicenter, Open Label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus (RAD001) With Basiliximab, Corticosteroids and Lower Levels Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Recipients |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Transplantation |
| Intervention type | Drug |
| Interventions | Everolimus |
| Enrollment | 80 |
| Start date | Nov 1, 2003 |
| Primary completion | Nov 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 2, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: